For the year ending 2025-12-31, FDMT had -$89,095K decrease in cash & cash equivalents over the period. -$109,618K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -140,109 |
| Stock-based compensation expense | 22,016 |
| Vesting of common stock warrants in return for services | 0 |
| Change in fair value of derivative liability | -52 |
| Depreciation and amortization | 4,694 |
| Amortization of right-of-use assets | 2,931 |
| Net accretion of discount on marketable securities | 4,734 |
| Prepaid expenses and other current assets | 424 |
| Other assets | 4,927 |
| Accounts payable | 6,773 |
| Accrued and other liabilities | 8,152 |
| Deferred revenue | -209 |
| Operating lease liabilities | -3,193 |
| Net cash used in operating activities | -109,082 |
| Purchase of marketable securities | 442,821 |
| Maturities of marketable securities | 350,384 |
| Acquisition of property and equipment | 536 |
| Net cash used in investing activities | -92,973 |
| Issuance of common stock upon exercise of stock options and vesting of rsus | 984 |
| Issuance of common stock under the offering program, net of issuance costs-Public Offering | 0 |
| Issuance of common stock under the offering program, net of issuance costs-Underwritten Offering | 93,540 |
| Issuance of common stock under the offering program, net of issuance costs-Atm Offering Program | 9,683 |
| Issuance of common stock - 2020 espp | 1,253 |
| Issuance of common stock under stock purchase agreement | 7,500 |
| Net cash provided by financing activities | 112,960 |
| Net decrease in cash and cash equivalents | -89,095 |
| Cash and cash equivalents, beginning of period | 149,336 |
| Cash and cash equivalents, end of period | 60,241 |
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)